• Skip to main content
  • Skip to footer

Akari Therapeutics

A Revolution in Treating Autoinflammatory & Orphan Diseases

Menu
  • HOME
  • ABOUT
    • Close
    • MANAGEMENT
    • BOARD OF DIRECTORS
  • AREAS OF FOCUS
    • Close
    • PEDIATRIC HSCT-TMA
    • GEOGRAPHIC ATROPHY (GA)
  • THE SCIENCE
    • Close
    • OVERVIEW
    • MODE OF ACTION
    • TARGET PATHWAYS
      • Close
      • C5 (COMPLEMENT SYSTEM)
      • LTB4 (LEUKOTRINE SYSTEM)
    • MOLECULES
      • Close
      • NOMACOPAN
      • OTHER NOMACOPAN-BASED MOLECULES
      • VOTUCALIS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • GENERAL MEETING OF SHAREHOLDERS
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & EVENTS
      • Close
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • INVESTOR RESOURCES
      • Close
      • INVESTOR FAQS
      • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • PUBLICATIONS
    • STORIES
  • CONTACT US

Press Release

Akari TX / January 4, 2023

Akari Therapeutics to Present at Biotech Showcase 2023

NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …

[Read more...] about Akari Therapeutics to Present at Biotech Showcase 2023

Akari TX / December 1, 2022

Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology, and Medtech/ Diagnostic Conference

NEW YORK and LONDON, December 1, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …

[Read more...] about Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology, and Medtech/ Diagnostic Conference

Akari TX / November 22, 2022

Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

NEW YORK and LONDON, November 22, 2022(GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …

[Read more...] about Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

Akari TX / November 10, 2022

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA 

NEW YORK and LONDON, November 10, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …

[Read more...] about Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA 

Akari TX / November 9, 2022

Akari Therapeutics to Participate in the Jefferies London Healthcare Conference

NEW YORK and LONDON, November 9, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …

[Read more...] about Akari Therapeutics to Participate in the Jefferies London Healthcare Conference

Next Page »

Footer

Akari TX

LONDON

75/76 Wimpole Street London W1G 9RT UK

T: +44 (0)20.8004.0261
E: info@Akaritx.com

NEW YORK

1460 Broadway
New York, NY 10036

T: 929.274.7510
F: 929.274.7553
E: info@Akaritx.com

For investor relations inquiries: IR@akaritx.com
For business development inquiries: BD@akaritx.com

REGISTERED ADDRESS

Akari Therapeutics, Plc is registered in England and Wales under number 5252842 and has its registered office at Highdown House, Yeoman Way, Worthing, West Sussex, BN99 3HH.

EXPANDED ACCESS POLICY

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access.  At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

Copyright © 2023 · Akari Therapeutics · Site Designed by Polus Digital, Inc.